Exploratory Study on the Efficacy and Safety of Mirogabalin and Duloxetine for Chemotherapy-Induced Peripheral Neuropathy

Supportive therapies, such as mirogabalin (M) and duloxetine (D), are used to manage chemotherapy-induced peripheral neuropathy (CIPN) associated with taxane- and platinum-based anticancer agents. This study compared the efficacy and safety of M and D in patients with CIPN. Patients newly initiated on M (32 cases) or D (10 cases) for CIPN at the Ogaki Municipal Hospital between July 2023 and October 2024 were included. The numerical rating scale (NRS) score, NRS change rates, and adverse events were compared between the two groups 1 month after initiating supportive therapy.